Comparative Pharmacology
Head-to-head clinical analysis: LABETALOL HYDROCHLORIDE IN DEXTROSE versus PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LABETALOL HYDROCHLORIDE IN DEXTROSE versus PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE.
LABETALOL HYDROCHLORIDE IN DEXTROSE vs PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at beta-1 adrenergic receptors (cardiac) and selective alpha-1 adrenergic receptors (vascular smooth muscle). Reduces heart rate, myocardial contractility, and peripheral vascular resistance.
Propranolol is a nonselective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
Adult: Initial 0.5-2 mg/min IV infusion, titrate to response; typical maintenance 2-8 mg/min. Max cumulative dose 300 mg.
Oral: 1 tablet (propranolol 40 mg / hydrochlorothiazide 25 mg) twice daily or as needed to control blood pressure; maximum propranolol 320 mg/day.
None Documented
None Documented
Terminal elimination half-life: 5-8 hours (adults); 8-12 hours (elderly); 2-4 hours (children). Clinical context: half-life may be prolonged in hepatic or renal impairment.
Propranolol: 3-6 hours (terminal) with significant interindividual variability; prolonged in hepatic impairment (up to 11 hours). Hydrochlorothiazide: 6-15 hours (terminal); prolonged in renal impairment (creatinine clearance <30 mL/min).
Renal: 40-60% as unchanged drug and metabolites; biliary/fecal: ~50% as metabolites; <5% unchanged in feces.
Propranolol: <1% unchanged in urine; extensively metabolized in liver, metabolites (4-hydroxypropanolol and others) excreted renally (90%) and fecally (10%). Hydrochlorothiazide: >95% renally excreted unchanged; negligible biliary/fecal elimination.
Category A/B
Category C
Alpha/Beta-Blocker
Beta-Blocker